Withings BeamO: The ‘Thermometer of the Future’ That Doubles as a Stethoscope and ECG

Withings’ BeamO, marketed as the “thermometer of the future,” packs a contactless thermometer, a digital stethoscope, and a 1-lead electrocardiogram into a single handheld gadget. After several weeks of testing, it’s clear the device aims to replace a medicine-cabinet staple with a miniature home diagnostic tool that connects to a companion app via Wi‑Fi or Bluetooth.

The thermometer reads temperature by moving the device from forehead to ear, with results color‑coded as normal, elevated, or high. The stethoscope records heart sounds in four chest positions and lung sounds in eight spots across the chest and back—each 15‑second recording guided by an on‑screen body diagram. Users need help for the back placements, and the device repeatedly warned of a “too noisy” environment even in a quiet room. To interpret those recordings, a doctor’s review is required; the app offers descriptions of what sounds should be like but cannot diagnose.

The ECG function records 30 seconds of heart activity. In Europe it can detect atrial fibrillation automatically, while U.S. users unlock that feature by having their first ECG reviewed by a board‑certified cardiologist—a free service that typically takes 24–48 hours. A Withings Plus subscription ($10/month or $100/year) adds up to four cardio check‑ups per year. The SpO2 sensor is built in but not activated in the United States.

BeamO sells for $250 and is FSA/HSA‑eligible; it includes a free one‑month trial of the subscription, a 30‑day device trial, and a two‑year warranty.

What a Multi-Sensor Device Means for Home Health Monitoring

Withings’ Bet on the Home Diagnostic Market

BeamO fits squarely into Withings’ broader vision of at‑home health tracking amplified by telehealth. The device isn’t designed to replace a doctor but to feed data into a remote‑consultation model—its stethoscope and ECG recordings become useful only when a clinician interprets them. That makes BeamO most attractive for people who already rely on telemedicine, those managing chronic cardiac or pulmonary conditions, or individuals facing barriers to in‑person visits such as mobility challenges, contagious illness, or transportation gaps.

Still, the product leaves gaps for everyday consumers. The stethoscope’s persistent noise warnings, the need for a second person to record lung sounds, and the requirement that a doctor review each recording add friction. At $250 plus an optional subscription, the value proposition is narrow: a basic thermometer costs a fraction of that, and the ECG feature—while cleared by the FDA—is hamstrung in the U.S. by the initial review step. The AI‑powered Withings Intelligence feature, still in beta, did little more than flag a reportedly higher temperature and ask for symptoms, underscoring that automated analysis isn’t ready to replace human judgment.

Nevertheless, BeamO highlights a direction where multi‑sensor devices become part of virtual‑first care. If Withings (or rivals) can close the gap between raw recordings and actionable insights—perhaps with clearer guidance on placement, better noise filtering, or more reliable AI interpretation—the “thermometer of the future” could evolve from a telehealth accessory into a genuine diagnostic companion.

Is BeamO Worth $250 for You? Key Takeaways from Testing

For consumers considering BeamO, the test experience points to three practical takeaways:

  • Ideal if you already use or need telehealth. The device shines when you have a doctor who can interpret stethoscope and ECG recordings remotely. If your primary care relies on in‑person visits, BeamO’s extra features may sit unused.
  • Not a replacement for a basic thermometer. If all you need is a quick temperature reading, a $10 digital thermometer will do the job. BeamO’s extra cost only makes sense if you’ll regularly use its heart and lung functions with a healthcare provider.
  • Know the activation requirements. In the U.S., the ECG’s AFib detection isn’t available until a cardiologist reviews your first tracing—a process that takes up to 48 hours. The SpO2 sensor remains inactive. Factor that in if you expected out‑of‑box cardiac alerts.
  • FSA/HSA eligibility softens the price tag. The $250 device is eligible for flexible spending accounts, and the 30‑day trial plus two‑year warranty offer a low‑risk trial period. Use the free one‑month Withings Plus trial to send one ECG for a cardio check‑up before committing to the subscription.